Skip to content

References: Probiotics, Prebiotics, and "Psychobiotics"

  1. Probiotics: Usefulness and Safety. National Center for Complementary and Integrative Health (NIH). A plain-language government overview of what probiotics are, how they are regulated, what the evidence shows for different conditions, and who faces higher risk. Source for the strain-specificity, regulation, and safety points in Sections 16.3 to 16.6. (The page's date label still says August 2019, although it now mentions the FDA's 2023 preterm infant warning; use the FDA press release below as the primary source for that warning.)

  2. Questions and Answers on Dietary Supplements. US Food and Drug Administration. Explains the 1994 DSHEA law, why the FDA does not approve supplements before they are sold, and why labels carry the "not evaluated by the Food and Drug Administration" disclaimer.

  3. FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants. US Food and Drug Administration, October 26, 2023. The press release behind the preterm infant warning in Section 16.6 and the At the Bedside case, including the 2023 death and the statement that no probiotic is approved as a drug for infants.

  4. Decoding a Probiotic Product Label. International Scientific Association for Probiotics and Prebiotics (Mary Ellen Sanders, updated 2025). A clear guide to reading strain names and CFU counts, and why counts at the end of shelf life matter more than counts at manufacture. ISAPP receives industry support, so read it alongside the government pages.

  5. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. American Gastroenterological Association, 2020. The guideline summary showing that probiotics for IBS, Crohn's disease, and ulcerative colitis are recommended only within clinical trials, with a few specific uses suggested.

  6. Expert consensus document: The ISAPP consensus statement on the scope and appropriate use of the term probiotic. Hill C, et al. Nature Reviews Gastroenterology & Hepatology, 2014. The scientific consensus definition of a probiotic used in Section 16.2. The abstract explains why a precise definition helps people tell products apart.

  7. Psychobiotics: a novel class of psychotropic. Dinan TG, Stanton C, Cryan JF. Biological Psychiatry, 2013. The paper that coined the word "psychobiotic." Its short abstract gives the original definition and notes that large placebo-controlled trials were still awaited.

  8. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Bravo JA, et al. PNAS, 2011. The influential mouse study of L. rhamnosus JB-1 described in Section 16.7, including the vagotomy experiment. Free full text.

  9. Lost in translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects. Kelly JR, et al. Brain, Behavior, and Immunity, 2017. The human trial of the same strain that found no effect in 29 healthy men. Read it next to the Bravo paper as a lesson in mouse-to-human translation.

  10. Strain-specific effects of probiotics on depression and anxiety: a meta-analysis. Rahmannia M, et al. Gut Pathogens, 2024. The 12-trial review discussed in Section 16.8, which found improvement on one depression scale but not on three others. Free full text.

  11. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. McFarland LV, Evans CT, Goldstein EJC. Frontiers in Medicine, 2018. A review of 228 trials showing that probiotic effects depend on both the strain and the disease. Free full text.

  12. Selective publication of antidepressant trials and its influence on apparent efficacy. Turner EH, et al. New England Journal of Medicine, 2008. The classic study of publication bias used in Section 16.8, comparing FDA records with published journal articles for 74 antidepressant trials.